Eukaryotic Programmed Cell Death Protein 1 (PD1) Homo sapiens (Human) Eukaryotic protein

CD279; PDCD1; SLEB2; HPD1P

Add to Cart Distributors
Overview
Properties
  • Source Eukaryotic expression, Host 293F Cell
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationMembrane
  • Molecular Mass 18.4kDa, Accurate 36-45kDa(Analysis of differences refer to the manual)
  • Residues & TagsPro21~Val170 with N-terminal His Tag
  • Buffer FormulationPBS, pH7.4, containing 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 95%
  • Isoelectric Point8.7
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Eukaryotic Programmed Cell Death Protein 1 (PD1) Packages (Simulation)
  • Eukaryotic Programmed Cell Death Protein 1 (PD1) Packages (Simulation)
  • Eukaryotic Programmed Cell Death Protein 1 (PD1) Figure. Gene Sequencing (Extract)
  • EPA751Hu61.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Sequence

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.pubmed:28545019
  • Потенциальные биомаркеры эффективности терапии ниволумабом при метастатическом почечно-клеточном раке:
  • АНАЛИЗ РЕЗУЛЬТАТОВ ЛЕЧЕНИЯ БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ ПОЧКИ, ПОЛУЧАВШИХ АНТИ-PD-1‑ТЕРАПИЮ В РАМКАХ ПРОГРАММЫ …
  • Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor ActivityPubmed: 30699956
  • Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated …Pubmed: 30807610
  • Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control StudyPubmed: 32085544

Recommend products